Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology (Nasdaq: OLMA) granted inducement stock options to five new employees to purchase an aggregate of 154,700 shares, effective May 1, 2026.

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) granted inducement stock options to five new employees to purchase an aggregate of 154,700 shares, effective May 1, 2026. The options vest over four years (25% after one year, then monthly over three years), have a 10-year term and an exercise price of $14.32 per share, equal to the last reported sale price on May 1, 2026. Awards were approved by the Compensation Committee and granted under the company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Argus May 5 session

+0.07% close to close Open Argus

Details

News Market Reaction – OLMA

In the May 5 session, OLMA gained 0.07%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine equity compensation: OLMA granted stock options on 154,700 shares ...

Analysis

This announcement details routine equity compensation: OLMA granted stock options on 154,700 shares to five new employees at an exercise price of $14.32, vesting over four years with a 10-year term. It follows a similar inducement grant disclosed on Apr 2, 2026. In the broader context of ongoing Phase 3 and preclinical programs, investors may focus on how such grants support talent retention while modestly increasing potential future share issuance.

Key Figures

Inducement option shares: 154,700 shares Number of new employees: 5 employees Option term: 10 years +5 more

Inducement option shares

154,700 shares

Aggregate stock options granted to five new employees effective May 1, 2026

Number of new employees

5 employees

Recipients of inducement stock options under 2022 Inducement Plan

Option term

10 years

Term of the stock options granted under the 2022 Inducement Plan

Exercise price

$14.32 per share

Equal to last reported Nasdaq sale price on May 1, 2026

Initial vesting cliff

25%

Vests on first anniversary of vesting commencement date

Monthly vesting period

36 months

Remaining options vest in equal monthly installments over three years

Current share price

$14.63

Price before article; slightly above new option exercise price

Shares outstanding (proxy)

87,346,132 shares

Common shares outstanding as of Apr 23, 2026 per DEF 14A

Historical Context

5 past events · Latest: Apr 29

5 events

1. Apr 29

   Board appointment

   24h Move

   +1.9%

   Added experienced biopharma executive to board as lead programs advance.

2. Apr 21

   Clinical data plans

   24h Move

   -0.6%

   Planned initial OP-3136 data and OPERA-02 poster at ASCO 2026.

3. Apr 17

   Preclinical data

   24h Move

   -1.4%

   Reported AACR preclinical data for palazestrant and OP-3136 combinations.

4. Apr 02

   Inducement grants

   24h Move

   +0.7%

   Announced stock option inducement grants to new employees under 2022 plan.

5. Mar 17

   AACR preview

   24h Move

   -3.3%

   Outlined upcoming AACR preclinical posters on palazestrant and OP-3136.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), stock options

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted under the Company's 2022 Inducement Plan ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"granted stock options to five new employees to purchase an aggregate of 154,700 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 154,700 shares of the Company's common stock, effective as of May 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $14.32 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on May 1, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Olema Oncology (OLMA) announce on May 4, 2026 about stock option grants?

Olema granted inducement stock options for an aggregate of 154,700 shares to five new employees. According to the company, awards were effective May 1, 2026 and approved under the 2022 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4).

What are the vesting terms for the OLMA inducement stock options granted May 1, 2026?

The options vest over four years: 25% vest after one year, then the remainder vests in 36 equal monthly installments. According to the company, vesting is subject to continuous employment through each vesting date.

What exercise price and term apply to Olema Oncology's (OLMA) May 1, 2026 option grants?

The options carry a $14.32 exercise price and a 10-year term. According to the company, $14.32 equals the last reported sale price of the common stock on Nasdaq on May 1, 2026.

How many employees received inducement grants and under which plan at OLMA (Nasdaq: OLMA)?

Five new employees received inducement stock options, totaling 154,700 shares, granted under the 2022 Inducement Plan. According to the company, the Compensation Committee approved the awards as inducements to employment.

Why did Olema Oncology (OLMA) disclose these inducement grants on May 4, 2026?

Olema disclosed the grants to comply with Nasdaq Listing Rule 5635(c)(4) for inducement awards to new employees. According to the company, the disclosure explains grant terms including vesting, exercise price, and plan authority.